Clinicopathological evaluation also suggests that RIZ1 hypermethylation is negatively correlated with tumor grade and patient age, and the RIZ1 promoter is hypermethylated in human glioblastoma cell lines. This evidence concerns the gene PRDM2 and glioblastoma.